Radiotherapy for glioblastoma in the elderly.
暂无分享,去创建一个
Luc Taillandier | Pierre-Yves Bondiau | Jean-Yves Delattre | Jérôme Honnorat | Philippe Colin | J. Honnorat | O. Chinot | P. Bondiau | K. Mokhtari | J. Delattre | G. Kantor | L. Taillandier | J. Guillamo | H. Loiseau | Olivier Chinot | A. Bissery | J. Mazeron | Karima Mokhtari | Hugues Loiseau | Marc Frenay | S. Cartalat‐Carel | M. Frénay | F. Keime-Guibert | P. Colin | Guy Kantor | Anne Bissery | Stéphanie Cartalat-Carel | Jean-Jacques Mazeron | Valérie Bernier | Maryline Barrié | E. Jadaud | Florence Keime-Guibert | Jean-Sébastien Guillamo | Eric Jadaud | Philippe Meneï | V. Bernier | M. Barrié | Philippe Meneï
[1] N. Bleehen,et al. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.
[2] P Schaffer,et al. Descriptive epidemiology of cerebral gliomas in France , 1997, Cancer.
[3] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[4] L. Junck,et al. Age influences chemotherapy response in astrocytomas , 1995, Neurology.
[5] L. Siu,et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Gross,et al. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Mega,et al. The Neuropsychiatric Inventory , 1994, Neurology.
[8] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[9] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[10] D. Osoba,et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires , 1996, Quality of Life Research.
[11] D. Osoba,et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. , 2005, The Lancet. Oncology.
[12] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[13] D. Osoba,et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K Takakura,et al. Subacute brain atrophy after radiation therapy for malignant brain tumor , 1989, Cancer.
[15] A. Gregor,et al. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma , 2003, Journal of Neuro-Oncology.
[16] J. Crowley,et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Bottomley,et al. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. , 2002, European journal of cancer.
[18] S. Preston‐Martin,et al. A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999 , 2005, Cancer.
[19] J. Dartigues,et al. Incidence of Central Nervous System Tumors in Gironde, France , 2004, Neuroepidemiology.
[20] V. Smith,et al. Therapeutic irradiation and brain injury. , 1980, International journal of radiation oncology, biology, physics.
[21] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[22] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Walker,et al. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.
[24] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[25] R. Hatlevoll,et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.